Table 1.

Selected studies examining the activity of anti-HER2 antibodies or antibody drug conjugates for NSCLC with HER2 mutation or a de novo HER2 amplification

References	Treatment	Type of study	HER2 alteration	No. of patients	PR (%)	DCRb (%)	Median PFS (months)	Median OS (months)
Mazières et al. [7]	Trastuzumab + chemotherapy	Retrospective	HER2 mutation	58a	50.9	75.5	4.8	13.3
Hainsworth et al. [8]	Trastuzumab + pertuzumab	Phase 2 basket	HER2 mutation	14	21	NR	NR	NR
Hotta et al. [9]	T-DM1	Phase 2	HER2 mutation	7	14.3	71.4	2.0	10.9
			Amplification	3	0	0
Li et al. [10]	T-DM1	Phase 2 basket	HER2 mutation	32c	34.3	87.5	5.0	NR
			Amplification	17c	41.1	100
Tsurutani et al. [11]	Trastuzumab deruxtecan	Phase 1	HER2 mutation	11	72.7	90.9	11.3	NR
Smit et al. [12]	Trastuzumab deruxtecan	Phase 2	HER2 mutation	42	61.9	90.5	14.0	Not reached

DCR disease control rate, No. number, NR not reported, OS overall survival, PFS progression-free survival, PR partial response

^aTwo patients received trastuzumab alone, one patient T-DM1

^bPartial response + stable disease

^cConcomitant HER2 mutation in 7 cases